A systematic review examining nutrition support interventions in patients with incurable cancer by Blackwood, Honor A. et al.
1 
 
A systematic review examining nutrition support interventions in patients with incurable 
cancer.  
Authors: Honor A Blackwood1, Charlie C Hall1,2, Trude R Balstad4,5, Tora S Solheim4,5, Marie 
Fallon2, Erna Haraldsdottir1,3,6, Barry J Laird1,2  
Affiliations: 
1St Columba’s Hospice, Centre for Education and Research, Edinburgh UK 
2Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh UK. 
3Queen Margaret University, Edinburgh UK 
4Cancer clinic, St. Olavs hospital, Trondheim University Hospital, Trondheim, Norway 
5Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, 
NTNU – Norwegian University of Science and Technology, Trondheim, Norway 
6School of Health Sciences, University of Iceland, Reykjavík 
Corresponding Author: Honor A Blackwood, St Columba’s Hospice, Centre for Education 
and Research, Edinburgh, UK  
email: hblackwood@stcolumbashospice.org.uk or barry.laird@ed.ac.uk  
T: 0044 131 551 1381 (ext. 303) 
 
Acknowledgement 
 This work was supported by The Nancie Massey Charitable Trust, Miss M B Reekie’s 
Charitable Trust and the P F Charitable Trust. 
The authors thank Marie Smith, Library & Knowledge Service Co-ordinator of NHS Fife for 




Purpose: Recent guidelines by the European Society for Clinical Nutrition and Metabolism 
(ESPEN) have advocated increased attention to nutritional support in all patients with cancer: 
however, little is known about the optimal type of nutritional intervention. The aim of this 
review was to assess the current evidence for nutrition support in patients with incurable cancer. 
Methods: This review was conducted in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis (PRISMA) guidelines. EMBASE, Medline and 
CINAHL were searched from 1990-2018. Evidence was appraised using a modified risk of 
bias table, based on guidance from the Cochrane Handbook for Systematic Reviews of 
Interventions. Results:  Sixty studies were assessed of which twelve met the eligibility criteria. 
Eleven studies examined body composition, with six studies reporting improvements in weight. 
Six studies examined nutritional status with three studies reporting an improvement. Nine 
studies examined nutritional intake with six showing improvements including significant 
improvements in dietary and protein intake. Ten studies examined quality of life, with six 
studies reporting improvements following intervention. The most common nutritional 
interventions examined were nutrition counselling and dietary supplementation. Conclusions: 
There is moderate quality evidence to support the need for increased attention to nutrition 
support in patients with incurable cancer; however, despite some statistically significant results 
being reported the clinical effects of them were small. Key questions remain as to the optimal 
timing for these interventions to be implemented (e.g. cachexia stage, illness stage, timing with 
anticancer therapy) and the most appropriate endpoint measures.  







Since the time of Hippocrates, cachexia has been associated with a poor outcome in 
patients with cancer.[1] Indeed, cancer cachexia results in increased mortality rates, with up to 
20% of cancer deaths related to malnutrition.[2, 3] 
Cachexia is not simply due to lack of adequate oral intake; rather, it’s pathophysiology 
is complex and includes a combination of systemic inflammation and hyper-metabolism.[4] 
This, in combination with decreased oral intake and reduced physical function means that 
anabolism is impaired, resulting in loss of skeletal muscle.  
With such a complex genesis it may at first seem daunting to address these multiple 
components however there is a plausible argument that multimodal therapies targeting each of 
these elements; inflammation, decreased oral intake and reduced physical function, is necessary 
to optimally treat cachexia.[5-7] 
 Appropriate nutritional intake is a key component of any intervention and this has 
recently been emphasized by the European Society for Clinical Nutrition and Metabolism 
(ESPEN) guidelines on cancer-related malnutrition and cachexia. It is now advocated that 
increased attention is paid to nutritional interventions for all patients with cancer. [8]    
Several key recommendations were subsequently made: nutritional intake should be 
screened regularly from the onset of cancer diagnosis, including those with advanced cancer; 
patients identified as having nutritional disturbance should undertake regular nutritional 
assessment including dietary intake, weight loss and body mass intake. [9] 
In patients with cancer the nutritional aim is often about maintaining or improving 
nutritional status, function and survival. [10] However, in patients with incurable cancer the aim 
is often focused on improving quality of life and minimising symptoms such as nausea and 
vomiting which may impact on their nutritional intake. [11]   
However, the evidence to support regular nutritional assessment in patients with 
incurable cancer is not clear. [9] There is a need to collate and evaluate the evidence concerning 
the clinical consequences of nutrition support via dietary interventions including nutrition 
counselling with or without the use of oral nutritional interventions. 
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The aim of this systematic review was to assess the current evidence for nutrition 
support via nutritional interventions implemented in patients with incurable cancer. 
Methods 
This systematic review was conducted in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines.[12] Ethical approval 
was not required. 
Search strategy and selection criteria 
Original Studies with adult patients (>18 years) with incurable cancer (defined as not 
curable but might receive antineoplastic treatment aiming to prolong life and/or alleviate 
symptoms), evaluating the effect of oral dietary interventions were included. Eligible studies 
also had to have defined outcome measures such as, body composition; including weight 
(measured in kg, pound or percent change in lean body mass (LBM), total body mass (TBM) 
or fat mass (FM), nutritional intake; including energy intake (measured as kcal, kJ or MJ, 
absolute intake and/or energy balance), nutritional status; which were measured using validated 
tools such as the Patient Generated Subjective Global Assessment (PG-SGA) [13] and 
measurement of QoL using patient reported outcome measures such as the European 
Organisation for Research and Treatment of Cancer – Quality of Life - C30  (EORTC QLQ-
C30) [14]. Both quantitative and qualitative trial designs were included. 
 Studies were excluded that evaluated the effect of either parental or enteral nutrition 
(including papers that evaluated mixed interventions that included enteral/parental nutrition). 
Studies were also excluded if the intervention was selected nutritional compounds such as 
certain vitamins, fatty acids, proteins or amino acids. Case reports, conference abstracts, 
systematic reviews or studies with ten or less participants were not included. Language was 
limited to English only.   
The literature search was conducted in the following electronic databases; MEDLINE, 
Embase and CINAHL, with all databases being searched from 1990-2018. The last search date 
was the 25th October 2018. The search was performed by an experienced librarian. The search 
strategy for all databases is reported in appendix 1 (supplementary material). Appropriate 




All titles retrieved from the literature search were reviewed (HB) and if potentially 
eligible, studies were retrieved in full and appraised independently (HB, BL and EH). If all 
three authors agreed that the studies met the eligibility criteria these were then included in the 
review. Any disagreements regarding a trial were discussed between the three authors and a 
consensus agreed. The PRISMA statement for reporting systematic reviews was used [12].  
Eligible studies are summarised (table 1) including risk of bias for each trial. Quality 
of studies was assessed by HB and CH using a modified risk of bias table, based on guidance 
from the Cochrane Handbook for Systematic Reviews of Interventions [15], and a summary 
table was developed (see table 2). The risk of bias for each patient-important outcome was 




Search results and selection of studies 
The literature search retrieved a total of 1139 papers (see Fig. 1). After screening of the 
titles and identifying any duplicates, a total of 60 studies remained. One thousand and eighteen 
studies were removed at title. After reviewing each study against the eligibility criteria, 48 
studies were excluded. Twelve studies were eligible, of which eight were RCTs [6, 16-22], three 
prospective observational studies [23-25] and one post hoc analysis study. [26]  
Twelve studies assessing a total of 1266 patients investigated the effect of nutritional 
interventions in patients with incurable cancer. Predominant cancer types were gastrointestinal 
(including pancreatic and colorectal) and lung, with over 40% receiving chemotherapy 
treatment. 
Nutrition counselling with or without oral dietary intervention 
Three studies (n=438) examined nutrition counselling with or without oral dietary 
intervention, two randomised controlled trials [16, 20] and one prospective observational study. 
[25] The prospective observational study examined nutrition counselling alone and the two 
RCT’s examined nutrition counselling alongside an oral dietary intervention. One RCT 
compared the effects of nutrition counselling alone, the effect of ONS alone, the effect of 
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nutrition counselling and ONS in combination or no intervention. [16] The other RCT compared 
nutrition counselling and IAtta with nutrition counselling alone. [20]   
Findings by Kapoor et al (2016) [20] reported that patients within the control arm had 
significantly decreased body weight (p=0.003), mid upper arm circumference (p=0.002) and 
body fat (p=0.002) by the end of the intervention. Although not significant, body weight gain 
was seen in the intervention group (p=0.08) as well as a significant increase of body fat (BF) 
(p=0.002) being observed. Patients in the intervention group also reported a significant 
improvement in fatigue (p=0.002) and appetite (p=0.006). 
Baldwin et al’s (2011) [16]  RCT was stopped early on advice of the independent data 
monitoring committee due to lack of efficacy. There was no significant difference in survival 
or QoL between the groups.  Patients in the intervention group weighed more at one year than 
those in control group, but no difference was seen between those receiving oral nutritional 
supplements (ONS) alone or the combination of ONS and dietary advice. There was no 
statistical difference between weight changes of non-survivors and survivors, however less 
weight loss was seen in the those who survived beyond 26 weeks.  
Multimodal therapies alongside chemotherapy  
Multimodal therapy e.g. dietary intervention and physical exercise, delivered alongside 
chemotherapy was examined in five studies (n=216) [6, 17, 21, 22, 24]; Four were RCT’s [6, 17, 21, 22] 
while the other was a prospective observational study.[24] 
Findings from Read et al (2006) [24] saw improvements in body composition including  
significant increase in mean weight at three weeks (p=0.03) with this remaining stable up to 
week nine. LBM also maintained throughout the nine weeks. Significant improvements were 
also seen in energy levels (p=0.03) between weeks three and nine, with all other QoL measures 
maintained. Dietary intake of n-3 fatty acids increased at week three and maintained up to week 
nine, this coincided with the commencement of the n-3 PUFA (polyunsaturated fatty acid) 
enriched ONS, this saw both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) 
improve significantly at week three and remaining high up to week nine. Significant decreases 
in nutritional intake including protein (p = 0.003) and energy (p =0.02) were seen following 
commencement of chemotherapy at the end of week three and nine. 
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Sanchez-Lara et al (2014) [21] also saw improvements in body composition. Significant 
differences were noted between groups (p = 0.01) for LBM which increased in the intervention 
group but decreased in the control group. The intervention group also had significantly greater 
energy and protein intakes (p<0.001) compared to those in the control group.  No overall 
difference was seen in the response rate or survival between either group, but fatigue, 
neuropathy and loss of appetite decreased significantly in the intervention group (p = ≤ 0.05 
for all). 
Breitkreutz et al (2005) [17] saw improvements in body composition including Fat Free 
Mass (FFM) increase in the intervention group compared to the control group. Body Cell Mass 
(BCM) decreased in the control group but was maintained within the intervention group, with 
significant intergroup differences between groups (p<0.05). QoL was also seen to improve 
more in the intervention group compared to the control group, but was not statistically 
significant. 
Oral dietary interventions  
Four studies examined the effect of oral dietary interventions alone (n=611). Two were 
RCT’s, [18, 19] one exploratory prospective observational study, [23] and one post hoc analysis 
study. [26]  
Fearon et al (2003) [18] showed that although consumption was below the recommended 
dose, the intervention group still showed a significant correlation between ONS intake and 
improved body composition, including weight gain (p<0.001) and an increase in LBM 
(p<0.036). Weight gain was also associated with improved QoL in the intervention group 
(p<0.01). However, no significant correlation was seen between intake and change in LBM 
between the two groups (p<0.043). Increased plasma EPA levels were also associated with 
weight and LBM gain (p<0.01). 
 Casas et al (2011) [23] showed significant differences in the intervention group for 
anxiety (p =0.023) and depression (p = 0.011), with QoL showing significant differences from 
baseline measurements between groups (p = 0.017). Significant differences were also seen 





Summary of Findings 
Twelve studies were identified, all from the outpatient setting. Following assessment 
of study quality using a modified risk of bias table, based on guidance from the Cochrane 
Handbook for Systematic Reviews of Interventions, [15] we have shown that there is moderate 
quality evidence to support the need for increased attention to nutrition support in patients with 
incurable cancer; however, despite some statistically significant results being reported the 
clinical effects of them were small. 
 
Body composition 
Eleven studies examined body composition as an outcome measure. Six reported an 
increase in weight [6, 17, 20, 22, 24, 26] of which one, looking at a combination of nutrition 
counselling and ONS alongside chemotherapy, reported an increase in FFM (p<0.05) and 
maintenance in BCM compared to the control group [17]. One study, examining the effects of 
IAtta, reported an increase in body weight gain (p=0.08) with significant increase in body fat 
(p=0.002) [20]. Only one study, examining nutrition counselling with the emphasis on restricting 
carbohydrates, reported significant weight loss following intervention. [25] Four studies 
reported weight stability [16, 18, 19, 21], although one of those studies, examining nutrition 
counselling and consumption of an n-3 PUFA enriched ONS alongside chemotherapy, reported 
an increase in LBM.[21] Of the six studies reporting an improvement in body composition, one 
study examined nutrition counselling alongside dietary intervention of IAtta [20], one study 
examined the effect of an n-3 PUFA enriched ONS [26] and four studies examined multimodal 
therapies alongside chemotherapy. [6, 17, 22, 24]. Of the six studies which saw improvements, all 
examined an oral dietary intervention, five of which were ONS, [6, 17, 22, 24, 26] with three of those 
being an n-3 PUFA enriched ONS and one examined IAtta. [20] 
 
QoL 
Eleven studies examined QoL as an outcome measure with eight studies reporting an 
improvement in QoL, measured on various subscales (three studies saw significant 
improvements, [20, 21, 23] and five studies saw non-significant improvements), [17, 18, 22, 25, 26] 
compared to the control group  and three studies reporting no difference between groups [16, 19, 
24]. Of the eight studies reporting an improvement in QoL, two were examining the effect of 
nutrition counselling alongside a dietary intervention [20, 25], three examined an oral nutritional 
intervention, [18, 23, 26] including one examining ice cream as a dietary intervention compared to 
ONS. [23] Three studies examined multimodal therapies alongside chemotherapy. [17, 21, 22] Of 
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the eight studies which saw improvements in QoL, seven examined an oral dietary 
interventions, of which six were ONS, [17, 18, 21-23, 26] with four of those being an n-3 PUFA 
enriched ONS, and one study examined IAtta as a dietary intervention. [20] The remaining study 
was examining nutrition counselling aimed at restricting carbohydrates. [25] 
 
Nutritional intake 
Nine studies examined nutritional intake as an outcome measure, with six studies 
reporting an improvement in nutritional intake [17-21, 26] including protein and energy intake 
(p<0.01), and three studies reporting a reduction in appetite loss [19-21]. Only one of these 
studies, examining nutrition counselling and consumption of an n-3 PUFA enriched ONS 
alongside chemotherapy, reported a decrease in intake following commencement of 
chemotherapy. [24] One study, examining nutrition counselling alongside an oral dietary 
intervention, failed to analyse nutritional intake due to compliance issues with the outcome tool 
used, [16] and one study, examining nutrition counselling and consumption of an n-3 PUFA 
enriched ONS alongside chemotherapy, showed no difference between groups. [22] Of the six 
studies reporting an improvement in nutritional status, one examined nutrition counselling 
alongside dietary intervention, [20] and three examined an oral dietary intervention, [18, 19, 26] and 
two examined multimodal therapies alongside chemotherapy. [17, 21] Of the six studies which 
saw improvements, all examined an oral dietary intervention, four  were examining ONS, [17, 
18, 21, 26], including 3 of those examining n-3 PUFA enriched ONS, one study examined IAtta 
as a dietary intervention [20] and the final study examined ice cream as a dietary intervention. 
[23] Of the six studies which saw improvements in nutritional intake, three of these also saw 
improved QoL [17, 20, 21], with three studies seeing improvements in body composition including 
weight [17, 20, 26], free fat mass (FFM) [17] and body fat (BF).[20]  
 
Nutritional status 
Six studies examined nutritional status as an outcome measure with three studies seeing 
improvement in nutritional status [20, 21, 23]. Three studies reported no differences between 
groups.[6, 22, 24] Of the three studies that reported improvements in nutritional status, one study 
examined ice cream as a dietary interventions compared to ONS [23], one study was examining 
nutrition counselling alongside the addition of IAtta [20] and one study examined nutrition 
counselling and the consumption of an n-3 PUFA enriched ONS alongside chemotherapy. [21] 
Of the three studies which saw improvements, all examined an oral dietary intervention, one 
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examined an n-3 PUFA enriched ONS, [21], one examined IAtta [20] and the last one examined 
ice cream as a dietary intervention, compared to ONS. [23] 
Discussion 
There is limited evidence as to the most effective nutrition intervention for patients with 
incurable cancer, despite various guidelines.[8, 27] This review examined the effects of nutrition 
support in patients with incurable cancer. 
The National Institute for Clinical Excellence (NICE) [27] guidelines and the ESPEN 
guidelines [8] highlight the need for early nutritional screening in order to identify patients who 
are malnourished. Diagnostic criteria for cachexia have been developed and used to classify 
patient’s degree of cachexia, these consider; food intake, catabolic drivers, muscle 
mass/strength and effect of cachexia on the patient.[4] Cachexia classifications highlight that if 
cachexia is present, it can develop progressively from pre-cachexia to cachexia and on to 
refractory cachexia which cannot be fully reversed by conventional nutrition support and leads 
to progressive functional impairment. The studies included in this review did not classify the 
stage of cancer cachexia in which interventions were delivered. It would be interesting in future 
work to assess optimal timings of delivery of nutritional interventions. Should the cachexia 
classification criteria be used routinely for cancer patients, alongside nutritional assessments 
in order to identify as early as possible, those who are not only malnourished but at risk of 
cachexia and to what degree? This should be considered for patients when they are initially 
diagnosed with cancer and regularly screened throughout their cancer journey to minimise the 
risk of developing malnutrition/cachexia complications and/or prevent further deterioration 
which may impact on their functional status.[28] 
Nutrition counselling is considered the most appropriate first line nutritional 
intervention [8, 27] and the findings herein support this. Further aspects however need to be 
considered including; who is the best person to conduct the nutritional intervention, when 
should this take place, and should advice be standardised.[29] Patients are often provided with 
nutritional advice at varying time points of their journey from different health professionals 
and advice can often be conflicting or incorrect. Symptoms as a result of deteriorating status 
or from cancer treatment also need to be taken into consideration when providing nutritional 
advice as these can often have a negative effect on oral intake.[30] The type of interventions 
within studies should therefore be clearly described for both the control and the intervention 
group as well as timeframes undertaken. 
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High attrition rates are common in studies involving palliative care patients, and this 
was also evident in the studies examined in this review, with attrition rates over 40% recorded 
in three studies [18, 20, 26], this is often due to the frail nature of this patient group leading to 
withdrawal and high dropout rates. [31] 
Appropriate outcome measures also need to be considered and it is imperative in 
palliative care that these are relevant to assess appropriate palliative goals of care. Various tools 
have been developed such as the PG-SGA [13] to measure nutritional outcomes but there is no 
defined consensus on which tools are most appropriate. Due to the nature of this patient group, 
patients can often be too unwell, frail or fatigued to complete self-completed measurements. 
This can lead to reporting bias whereby frailer patient data is not included or missing. [32, 33] 
Limitations 
Relevant studies may have been missed in this review, despite a thorough search 
strategy being implemented, however we believe we identified all appropriate studies. Meta-
analysis of studies was not possible due to the differences in trial designs. Multiple assessors 
assessed study quality to limit any risk of bias, and any discrepancies were discussed in detail, 
then agreed upon. Baldwin et al [16] highlights that although RCT’s are the gold standard these 
are difficult to undertake for nutritional intervention studies. They argue it is often impossible 
to blind both the participants and the person undertaking the intervention or to have a placebo 
for the control group which can often then lead to bias [29]: indeed this was the case for most of 
the studies included in this review. This study also reviewed observational studies, which are 
often seen as inferior to RCT’s due to high risk of confounding factors and selection bias of 
patients. [34]  
 
Conclusion 
This review demonstrates moderate evidence for nutrition support in patients with 
incurable cancer, which supports the recommendations by ESPEN for increased attention to 
nutritional support in this patient group. Further high-quality studies are needed in order to 
identify the most appropriate types of nutritional interventions. 
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Table 1: Study summaries 
Author/year Study type Participants Intervention Intervention 
specifics 
Control Main outcomes 
(measures) 
Main findings Risk of bias  
Breitkreutz 










Stage T2-T4 – all 
metastatic. All 










Group B - Usual 
care + ONS 
(providing 20 non-
protein kcal/kg per 
day; 100ml 
contained 9.3g of 
fat) + nutrition 
counselling every 
14 days.  
Nutritional target 
for both groups was 
35 non-protein 
kcal/kg per day + 
1.1g of protein/kg 
per day.  
8 weeks. 
Group A - Usual 
care + nutrition 
counselling every 
14 days 
Changes in body 
composition 





FFM increased significantly in Group B compared 
to Group A (P<0.05) after 8 weeks. 
BCM significantly decreased in group A compared 
to maintaining in group B (not statistically 
significant) 
QoL improved more in Group B compared to group 
A (not statistically significant). 
Unclear 







N = 358  
Metastatic or locally 
advanced cancer of 
the GI tract, non-
small cell lung or 
mesothelioma all 








Randomly allocated to 
receive nutrition 
counselling via 
dietitian, ONS or 
nutrition counselling 
via dietitian plus ONS 
+ followed up weekly 
over a 6-week period. 
No intervention Mortality 





Author/year Study type Participants Intervention Intervention 
specifics 
Control Main outcomes 
(measures) 
Main findings Risk of bias  









ONS Consumption of 2 
energy + protein 
dense, n-3 PUFA 
enriched (1.1g EPA 
each) ONS. 
8 weeks. 
Consumption of 2 
isocaloric ONS 




(Wt., LBM, BIA, 
TBW), intake (3-
day food diary) + 
QoL (EORTC-
QLQC30) 
Significant differences in energy + protein intake + weight 




Solheim et al 




N = 46 
Stage 3/4 non-small 
cell lung and 
pancreatic cancer 








once daily, two x 
220ml 1g n-3 PUFA 





exercises weekly + 3 













the control arm) 
Compliance acceptable in all components other than the 
ONS (48%). Plasma EPA levels increased in both groups 
significantly higher in treatment arm. Mean weight 
increase (1.29%) seen in intervention group compared to 
wt. loss in control group (P = 0.001). No statistical 
differences were seen in muscle mass, physical activity, 
nutritional status or intake between groups. 
High 











ONS 2 x n-3 PUFA 
enriched (1.1g EPA 
each) + antioxidant 
enriched ONS daily + 
usual diet. 
8 weeks. 
2 x ONS (without n-3 
+ antioxidants) + 
usual diet. 
Body composition 
(Wt., BIA, TBW, 
LBM), dietary 
intake (3-day diet 




Mean rate wt. loss at enrolment 3.3kg/month. 
Consumption of ONS below recommended dose. 
Intervention group showed significant correlation between 
ONS intake + wt. gain (P<0.001) + increase in LBM 
(P<0.036). No significant correlations in control group. 
Significant correlation between intake and change in LBM 
between groups (P<0.043). Wt. gain was associated with 
improved QoL in intervention group (P<0.01). Increased 




Author/year Study type Participants Intervention Intervention 
specifics 
Control Main outcomes 
(measures) 
Main findings Risk of bias  






N = 70 




Ice cream Group 1: 2 x 90g ice 
cream servings daily.  
Duration not stated 
Group 2: 200ml ONS 
of 2-3 daily shots 
QoL (HADS and 
EORTC QLQ C30) 
Significant differences seen in group 1 for anxiety (p 
=0.023) + depression (p = 0.011). QoL significantly 
different from baseline between groups (p = 0.017). 
Significant differences between groups in global scale (p = 
0.016) + fatigue scale (p = 0.007). 
Low 



















Wine Patients randomly 
assigned to one of two 
treatment arms. 
Treatment arm 1 – 
white wine with <15% 
alcohol content twice 
daily + ONS. 
3-4 weeks.  
Treatment arm 2 – 








48% pts in wine arm + 37% pts in ONS arm reported 
improvements in appetite (not significantly improved). 







Author/year Study type Participants Intervention Intervention 
specifics 
Control Main outcomes 
(measures) 
Main findings Risk of bias  





N = 63 
Free living 
cachectic female 








30 min nutrition 
counselling + 100g of 
Improved Atta (IAtta - 
nutritious flour mix) - 
consumed in addition 
to normal dietary 
intake. Appointments 
every fortnight.  
Physical activity also 
encouraged in pts. 
6 months 
30 min nutrition 




status (Body wt. 
MUAC, SFT, BF%)  
+ QoL (EORTC 
QLQ C30) 
Pts in control group had significantly decreased body 
weight (P = 0.003), mid–upper-arm circumference (P = 
0.002) + body fat (P = 0.002) by end of intervention. Body 
weight gain in intervention group (not statistically 
significant P = 0.08) + significant increase of body fat (P = 
0.002) was observed. Pts reported a significant 
improvement in fatigue (P = 0.002) + appetite scores (P = 
0.006) under quality-of-life domains at end of intervention. 
Unclear 





N = 23 
Histologically 
confirmed diagnosis 







Pts were instructed to 
consume 2 x 1.09g n-
3 PUFA enriched 
ONS. 
Chemotherapy 
commenced at wk. 4 + 
repeated every 2 wks. 
9 weeks. 
No control Nutritional status 
PG-SGA), body 
composition (BIA, 








Significant increase in mean weight at 3 weeks (p=0.03). 
LBM was maintained (not statistically significant). Protein 
+ energy intake significantly decreased after 
commencement of chemo (protein p=0.003, energy 
p=0.02). Significant increase in energy levels (p=0.03) and 
overall wellbeing (P=0.05). All other QOL measures were 
maintained (not significantly significant). PPL EPA levels 
increased significantly over the 1st 3wks. Mean CRP 
increased over the first 3 wks. (p=0.004) but decreased to 
baseline levels by end of trial. There was a significant 
correlation between plasma IL-6 and IL-10 concentrations 




Author/year Study type Participants Intervention Intervention 
specifics 
Control Main outcomes 
(measures) 
Main findings Risk of bias  
Sanchez-Lara 




N = 112  
Stage IIIb + IV 
histologically 






Standardised menus + 
2 x n-3 PUFA 
enriched ONS. 
Both groups had 
isocaloric diets. 




(AUC6) every 3 wks. 
for at least 2 cycles 
(with max 6 cycles) 
 
Duration not stated 
 
Standardised menus 
of 1400, 1600, 1800, 
2000 or 2200kcal. 




(AUC6) every 3 wks. 
for at least 2 cycles 
(with max 6 cycles) 
 
Effect on body 
composition (Wt. 







(EORTC QLQ C30 
+ QLQ LC13), 
response + toxicity 
to chemo (CTCAE) 
+ survival. 
Intervention group had significantly greater energy 
(P<0.001) + protein (P<0.001) intakes compared to control 
group. LBM increased in intervention group but decreased 
in control group with significant differences seen between 
groups (p = 0.01). No difference in response rate or overall 
survival between groups. Fatigue, neuropathy + loss 
appetite significantly decreased in intervention group with 
a significant difference seen between groups. 
High 
Tan-Shalaby 













Pts were allowed 20-
40 g CHO/day during 
a 2-day screening 
period. Pts were 
advised on grocery 
shopping, + menu 
planning. 
Consumption of high 
carbohydrate foods 
were restricted. 
Calories and protein 
not restricted. 
16 weeks 
No control Safety + feasibility 
(EORTC QLQ C30) 
All lost significant wt. with hematologic, biochemical + 
lipid tests remaining stable. QoL scores remained stable (not 
statistically significant). No significant correlations 
between serum glucose, ketones or lipids. Responders 
(stable disease or partial responders) lost statistically more 




Author/year Study type Participants Intervention Intervention 
specifics 
Control Main outcomes 
(measures) 
Main findings Risk of bias  





N = 13 














2 n-3 PUFA enriched 








intake (food diary), 
tolerability 
(EORTC QLQ C30) 
+ chemotherapy 
compliance. 
Intervention group significantly increased wt. after 
intervention + better scores in important domains of 
HRQoL, compared to controls (not statistically significant). 
Supplemented group did not experience interruptions in 
chemo treatment compared to control group, with more 

































































































































Baldwin et al [16]  
 
RCT Y Y N Y Y N Low 
Bauer et al [26] Post hoc analysis N/A N/A N/A N Y  Unclear 
Breitkreutz et al 
[17] 
 
RCT U/C U/C U/C Y Y N Unclear 
Casas et al [23] Prospective observational study N/A N/A N/A N Y N High 
 
Fearon et al [18] RCT Y Y Y Y Y  Low 
Jatoi et al [19] 
 
RCT Y U/C Y Y Y  Low 
Kapoor et al [20] 
 
RCT U/C U/C U/C Y Y  Unclear 
Read et al [24] 
 
Prospective observational study N/A N/A N/A Y Y  Low 
Sanchez-Lara et 
al [21]  
 
RCT Y Y N Y Y  Low 
Tan-Shalaby et 
al [25]  
 
Prospective observational study N/A N/A N/A Y Y N Low 
Solheim et al [6] 
 
RCT – open label Y U/C X Y Y  Low 
Trabal et al [22] 
 
RCT – open label U/C U/C N N Y N High 







*Risk of bias  Definition (Cochrane Handbook for Systematic Reviews of Interventions) [15] 
HIGH 
 
Plausible bias that seriously weakens confidence in the results. 
 





Plausible bias that raises some doubt about the results. 
 
Table 3: Summary of Findings: (Modified due to study types) 
Patient- Important 
Outcomes  
Studies N= Total Participants** † (Breakdown per outcome 
measure 
Risk of bias  Comments 





Euro-QoL EQ-5D (110) 
QLQ-LC13 (84) 
DATA form (15) 
HADS (70) 
LASA scale (23) 
Low Improvements seen in two studies of high-quality evidence, 
two studies of low quality of evidence and two studies where 
quality of evidence was unclear. Four further high-quality 
evidence studies and one study where quality of evidence was 
unclear, reported no differences.  
 
Body composition  11 [6, 16-
22, 24-26] 
n = 710 
 
Weight (594) 










Low Improvements seen two high-quality evidence studies, one low-
quality evidence study and three studies which it was unclear 
regarding quality of evidence. Of the other studies reporting on 
body composition. Four high, quality evidence studies reported 
weight stability with one high quality study reporting weight 
loss following intervention. Limitations were seen in the 
studies. 
 
Nutritional status  6 [6, 20-24] n =255 
 
Low Improvements in nutritional status were seen in three studies, 





AveS (41)   
where quality of evidence was unclear. The remaining three 
studies reporting no differences between groups. 
Nutritional intake  9 [16-22, 
24, 26] 
n = 658 
 
Food diaries (424) 
24 hr dietary recall (32) 
IMS-FFQ (32) 
NCCTG (118) 
SNUT (food frequency questionnaire) (84)  
Low 
 
Improvements in nutritional intake was seen in six studies. 
Three studies were of high-quality evidence with three studies, 
quality of evidence was unclear. Of the remaining studies to 
report on nutritional intake, one was unable to analyse the data 
due to compliance issues, one study showed no difference 
between groups. Only one study showed a reduction in intake 
following commencement of treatment. 
** Total participants include final numbers analysed within studies for each outcome as opposed to table 1 showing ‘n’ as numbers enrolled in to each trial. 
†Some studies used more than 1 tool to assess an outcome 
 
Abbreviations 
Patient generated subjective global assessment 
(PG-SGA) 
Subjective global assessment (SGA) 
Muscle mass (MM) 
Mid upper arm circumference (MUAC) 
Patient (Pt.) 
Body weight (BW) 
Body fat percentage (BF%) 
National Cancer Institute common toxicity criteria 
for adverse events (CTCAE)  
 
 
Skin fold thickness (SFT) 
Lean Body Mass (LBM) 
Total body water (TBW) 
Fat Mass (FM)     
Cancer (Ca) 
Weight (Wt.) 
Bioelectrical impedance analysis (BIA) 
Disease and treatment assessment form (DATA) 
Oral nutritional supplement (ONS) 
Free fat mass (FFM) 
Total body fat (TBF) 
Body cell mass (BCM)  
Extra cellular mass (ECM) 
European organisation for research and treatment 
of cancer quality of life (EORTC-QLQ-C30) 
Euro QoL EQ 5D 
National Cancer Institute Common Toxicity 
Criteria (NCICTC) 
Functional assessment of anorexia/cachexia 
treatment (FAACT) 
Health related quality of life (HRQoL) 
Hospital anxiety and depression scale (HADS) 
Linear analog scale assessment scale of quality of 
life (LASA scale) 
North Central Cancer treatment group (NCCTG) 

























Fig 1. Literature search process
Records identified through database 
searching 



























Records after duplicates removed 
(n = 1078) 
Records screened 
(n = 1078) 
Records excluded (n = 1018) 
 Systematic review (5) 
 No nutritional intervention (512) 
 Mixed cancer stages (106) 
 Article (20) 
 Non-cancer participants (109) 
 Enteral/Parental intervention (125) 
 No intervention (14) 
 Guidelines (4) 
 Abstract (99) 
 Protocol (5) 
 Case study (8) 
 Non-human participants (3) 
 Alternative dietary intervention i.e. amino acid (1) 
 <10 participants (4) 
 Unclear re cancer stage (3) 
 
Full-text articles assessed for 
eligibility 
(n = 60) 
Full-text articles excluded, with reasons (n = 48) 
 Abstract (6) 
 Enteral/Parental intervention (4) 
 Mixed cancer stages (17) 
 Protocol (1) 
 Outcome measures (2) 
 Unclear re cancer stage (1) 
 Alternative dietary intervention i.e. amino acid 
(16) 




Studies included in review 





Appendix 1: Search Strategy (supplementary material) 
CINAHL strategy (librarian).docx 
Embase strategy (librarian).docx 
MEDLINE strategy (Librarian).docx 
 
 
